AGER-peptides and use thereof
    14.
    发明授权
    AGER-peptides and use thereof 有权
    AGER-肽及其用途

    公开(公告)号:US09291621B2

    公开(公告)日:2016-03-22

    申请号:US11795282

    申请日:2006-01-18

    摘要: The present invention relates to the identification, functionality and use of domains from the N terminus of the receptor for Advanced Glycation End Products (AGER). These domains, called receptor multimerization epitope (RME), are highly conserved in all AGER protein sequences. They represent the mediators for AGER self-association and heteromerization with other proteins. The invention likewise relates to the identification, functionality and use of peptides derived from the C domain of AGER (AGER-CDP). The AGER RMEs and AGER-CDPs of the invention are suitable as target for identifying AGER ligands which modulate the natural ligand interaction; as immunogen for active or passive immunization of individuals, as diagnostic means for identifying immunogenic reactions, and as peptide ligands for modulating protein-protein interactions involving AGER.

    摘要翻译: 本发明涉及来自高级糖化终产物(AGER)的受体的N末端的结构域的鉴定,功能和用途。 称为受体多聚表位(RME)的这些结构域在所有AGER蛋白质序列中都是高度保守的。 它们代表AGER与其他蛋白质自身结合和异源化的介质。 本发明同样涉及衍生自AGER(AGER-CDP)的C结构域的肽的鉴定,功能和用途。 本发明的AGER RME和AGER-CDP适用于鉴定调节天然配体相互作用的AGER配体的靶标; 作为用于个体的主动或被动免疫的免疫原,作为用于鉴定免疫原性反应的诊断手段,以及用于调节涉及AGER的蛋白质 - 蛋白质相互作用的肽配体。